SCHEMBL20945200

SCHEMBL20945200

O=c1[nH]nc(OS(=O)(=O)C(F)(F)F)c2ccc(Br)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 1/20 0.43
▸ WDR77 Q9BQA1 1/20 0.43
▸ DYRK1A Q13627 4/20 0.36
▸ FLT3 P36888 3/20 0.36
▸ JAK2 O60674 3/20 0.36
▸ CHEK1 O14757 3/20 0.36
▸ PIM1 P11309 2/20 0.36
▸ PRKD3 O94806 2/20 0.36
▸ MAP4K4 O95819 2/20 0.36
▸ CSF1R P07333 2/20 0.36
▸ CLK2 P49760 2/20 0.36
▸ MAP4K2 Q12851 2/20 0.36
▸ NTRK3 Q16288 2/20 0.36
▸ AURKB Q96GD4 2/20 0.36
▸ CLK4 Q9HAZ1 2/20 0.36
▸ AURKA O14965 1/20 0.36
▸ DAPK3 O43293 1/20 0.36
▸ PAK4 O96013 1/20 0.36
▸ ABL1 P00519 1/20 0.36
▸ NTRK1 P04629 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20944947 0.95 PRMT5 (0.40) PRMT5WDR77DYRK1AFLT3JAK2
SCHEMBL25546298 0.84 ELANE (0.35) PRMT5WDR77CHEK1PIM1RPS6KA3
SCHEMBL25547517 0.82 ENPP1 (0.46) DYRK1AGSK3AGSK3BROCK1HTR1A
SCHEMBL31384290 0.82 ENPP1 (0.46) DYRK1AGSK3AGSK3BROCK1HTR1A
SCHEMBL20945106 0.82 ATM (0.46) PRMT5PARP1
SCHEMBL31384311 0.82 ATM (0.46) PRMT5PARP1
SCHEMBL30319336 0.81 HTR1A (0.33) HTR1AHTR1DHTR1B
SCHEMBL29426556 0.81 PRMT5 (0.46) PRMT5WDR77DYRK1AFLT3JAK2
SCHEMBL26732891 0.81 PRMT5 (0.46) PRMT5WDR77DYRK1AFLT3JAK2
SCHEMBL25546304 0.80 ALDH1A1 (0.33) ALDH1A1HTR1AHTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109415345-B Pyridazinone-based broad-spectrum anti-influenza inhibitors 豪夫迈·罗氏有限公司 2022-01-11 — — CN disclosed
EP-3478671-B1 PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS HOFFMANN LA ROCHE (CH) 2020-05-13 — — EP disclosed
US-10597380-B2 Pyridazinone-based broad spectrum anti-influenza inhibitors HOFFMANN-LA ROCHE INC. (US) 2020-03-24 — — US disclosed
US-20190127349-A1 PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2019-05-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127349-A1 PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS ABCG2, PIR, PRNP PRMT5 3081/4885WDR77 3121/4885DYRK1A 1048/4885
US-10597380-B2 Pyridazinone-based broad spectrum anti-influenza inhibitors ABCG2, PIR, PRNP PRMT5 3081/4885WDR77 3121/4885DYRK1A 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback